Carbamazepine versus sulthiame in treating benign childhood epilepsy with centrotemporal spikes

Uri Kramer, Eli Shahar, Nathanel Zelnik, Tally Lerman-Sagie, Nathan Watemberg, Yoram Nevo, Bruria Ben-Zeev

Research output: Contribution to journalArticlepeer-review


We compared the therapeutic efficacy of carbamazepine versus sulthiame in patients with benign childhood epilepsy with centrotemporal spikes. Drug efficacy was evaluated only in those patients who initiated treatment with any drug after at least three seizures. Thirty-eight patients who received carbamazepine and 18 patients who received sulthiame were included in the analysis. Cessation of seizures was observed in 73.6% of the former and in 66.7% of the latter (P = not significant). Five of eight patients who were switched to sulthiame after failing carbamazepine became seizure free, whereas none of the three patients who failed sulthiame became seizure free after being switched to carbamazepine. The rate of drug discontinuation owing to adverse reaction was 15% in carbamazepine and 14.3% in sulthiame. Normalization of interictal epileptiform activity on electroencephalography was seen more often following treatment with sulthiame (71%) than with carbamazepine (42%) (P = not significant). No significant differences between these two medications were found in the treatment of benign childhood epilepsy with centrotemporal spikes in this small patient sample.

Original languageEnglish
Pages (from-to)914-916
Number of pages3
JournalJournal of Child Neurology
Issue number12
StatePublished - 1 Dec 2002
Externally publishedYes


Dive into the research topics of 'Carbamazepine versus sulthiame in treating benign childhood epilepsy with centrotemporal spikes'. Together they form a unique fingerprint.

Cite this